https://www.fda.gov/media/151707/download

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. In a developmental toxicity study in rats with COMIRNATY there were no vaccine-related effects on female fertility [see Use in Specific Populations (8.1)].

Auf dem Beipackzettel steht auch, dass die Wirksamkeit und Sicherheit bis einschließlich 15 Jahre nicht nachgewiesen ist.

8.4 Pediatric Use
Safety and effectiveness of COMIRNATY in individuals 16 through 17 years of age is based on safety and
effectiveness data in this age group and in adults [see Adverse Reactions (6) and Clinical Studies (14.1)].
The safety and effectiveness of COMIRNATY in individuals younger than 16 years of age have not been
established.

Trotzdem wird Comirnaty ab 12 von der STIKO empfohlen

Das ist die letzte Version des Beipackzettels vom August